title: [Neoplasms stem cells play an important role in resistance of laryngeal squamous cancer to chemoradiotherapy].
abstract: OBJECTIVE
  To determine an approach enriching cancer stem cells from laryngeal cancer cell line. To investigate whether laryngeal cancer stem cells in chemoradiotherapy have the characteristic of resistance.
  
  
  METHODS
  CD133+ cells and CD133- cells was detected and isolated from Hep-2 cell line by fluorescence activated cell sorting technology. The cytotoxicities of cisplatin and radiation were investigated by cell counting kit-8(CCK-8) assay. The apoptosis and cell cycle was analyzed with flow cytometry.
  
  
  RESULTS
  CD133+ cells accounted for a fraction of (2.43 +/- 0.77)% in Hep-2 cell line. CD133+ cells have a more obvious characteristics of cancer stem cells. Different cisplatin and radiation concentrations of for two cell have inhibition, in a certain concentration range and the dosage dependence. Cisplatin and radiation had synergistic inhibitory effects with CD133- cells on the growth of two cell. Moreover, cell cycle arrest at G0/G1 phase and more apoptosis was induced by synergistic combination. Different concentrations of cetuximab for Hep-2 cells have inhibition, in a certain concentration range and time and the dosage dependence. The half maxial inhibitory concentration (IC50) of cetuximab to Hep-2 cells on 24 h was 1 036.84 microg/L. Cisplatin and radiation had synergistic inhibitory effects with cetuximab on the growth of Hep-2 cell line. Moreover, cell cycle arrest at G0/G1 phase and more apoptosis was induced by synergistic combination.
  
  
  CONCLUSIONS
  Compared with CD133- cells, CD133+ cells subpopulation exhibited extraordinary cancer stem.
authors: Rui
authors: R
authors: Han
authors: Hui
authors: H
authors: Huangfu
authors: Wei
authors: W
authors: Gao
authors: Chunming
authors: C
authors: Zhang
authors: Yangzi
authors: Y
authors: Jin
authors: Zhuo
authors: Z
authors: Li
authors: Binquan
authors: B
authors: Wang
mesh_terms: D000071916:AC133 Antigen; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D002453:Cell Cycle; D045744:Cell Line, Tumor; D000068818:Cetuximab; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000528:radiation effects*; D010455:Peptides / Q000032:analysis; D011836:Radiation Tolerance
chemical_list: D000071916:AC133 Antigen; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000970:Antineoplastic Agents; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D000068818:Cetuximab; D002945:Cisplatin